Skip to main content

Table 3 Number of tender points and tender joints

From: Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study

Parameters

Baseline (n = 16)

6 weeks (n = 15)

10 weeks (n = 13)

18 weeks (n = 14)

32 weeks (n = 11)

Tender points

4.1 ± 5.6

2.0 ± 3.1

2.1 ± 3.4

1.6 ± 2.9

2.4 ± 3.3

Tender joints

4.0 ± 7.5

1.0 ± 1.8

1.1 ± 1.6

1.2 ± 1.9

0.3a ± 0.5

  1. Results are given as mean ± standard deviation. aDenotes statistical significance of the observed median change-from-baseline value with P ≤ 0.05 by Wilcoxon signed rank test. Almost all patients had no swollen joints at baseline or subsequent time points.